赛诺菲与Evotec达成2.5亿欧元战略合作

qing6628

赛诺菲与Evotec达成2.5亿欧元战略合作5 |  N) S# Y3 c7 P9 p
来源：生物谷 2015-03-21 10:55
- A9 s& @3 v. i/ a, u8 f! N8 z" i1 X6 m7 e

0 V. M/ h! ?6 O5 i, @' U: Y& O2015年3月21日讯/生物谷BIOON/--近日，赛诺菲与Evotec结束了长达5年的战略联盟谈判，同意为其提供2.5亿欧元投资，其中包括4000万现金欧元的预付款。5 f, |1 j5 Q; y/ C. l2 R

. r, t6 w) B! jEvotec将会获得赛诺菲在图卢兹的设施以及各项支持，用于支撑药物研发合作。包括与生物技术部门、风险投资与学术合作伙伴共同筛选与鉴定临床前候选药物分子等。
2 m; J( @$ X* k+ F! \5 E, h. T! m' Q6 D0 c+ c; q
Evotec表示，将会在未来五年内为赛诺菲提供长期的新药研发服务，服务中心是位于图卢兹的小分子筛选平台，并且会接管赛诺菲的全球化合物筛选数据库。9 ?5 j7 w: s- K, H3 x9 i7 Y& y
0 |" @; z" x0 ^
秉持“创新、突破”的原则，两家公司将会联合各自的数据库，并且向Evotec的商业合作伙伴提供筛选资源，创造一个大约170万个化合物分子的大型筛选平台。
8 V$ ?! Y3 I1 P0 ~; ^6 D
2 q9 g$ t7 G' t$ y- b0 L/ O- [除此之外，Evotec和赛诺菲将会联合推进肿瘤相关的产品组合投资项目，包括二者在合作前关于试验性新药的五个高级临床项目以及进一步研究的阶段投资。) D5 w$ \5 k5 a- d
8 W# a& B; h2 u5 c3 \$ N, a/ H( P
Evotec的董事长Werner Lanthaler表示，两者的合作支持了双方的长期战略发展计划，并且为股东创造了重要的价值，而不需要稀释资本。同时赛诺菲的全球研发董事长Elias Zerhouni也表示，二者的合作将会为雇员创造更多的业内机会，并为行内的局部生态做出贡献。(生物谷Bioon.com）( @- h5 d% G' N# a, x

! T' B3 p6 r/ f& b原文 Sanofi and Evotec seal 250m-Euro strategic alliance. C9 ]( p  W& z* C. o  }. v

; \  `5 y' z: }; C! p- p0 g+ rSanofi and Evotec have now concluded negotiations over a five-year strategic alliance giving the German group 250 million Euros， including more than 40 million Euros upfront in cash.
/ p6 ?, |$ F5 e8 b; e" \3 J8 {9 f, M$ A3 B; c8 h  a8 f" f# z
The move will see Evotec acquire Sanofi’s troubled operations in Toulouse， to support collaborative research in drug discovery from screening to identification of preclinical candidates with the firm’s biotech， venture capital and academic partners.
, X# i; y6 v( S- a/ l8 g5 Z+ ]! a% ^7 j
Evotec said it will provide a broad range of long-term drug discovery services to Sanofi over the next five years， centred on the core small-molecule discovery platforms in Toulouse， and will take over management of the French drugmaker’s global screening compound library.
! X  R- V4 e. s; W+ c' {3 s8 M: H
And， in a “first-in class， ground-breaking 'open innovation initiative’，” both groups will combine their libraries and offer them for screening to Evotec’s business partners， creating “one of the largest and most valuable sources of starting points for drug discovery with approx. 1，700，000 compounds available to screen”./ ?: R1 V! E1 X7 F

8 a, j* r2 Y: I% B& L7 k- B# kElsewhere， Evotec and Sanofi will jointly push forward a portfolio of primarily cancer-related projects - including five advanced， preclinical projects and further discovery-stage assets - to Investigational New Drug status or other value inflection points before partnering them.
& Y  j  D( \4 J+ T( n1 }& L9 i% _* s, U8 l
Werner Lanthaler， Evotec’s chief executive， said the transaction “supports our long-term strategic growth plans” and “brings significant value to [our] shareholders without the need for dilutive financing”， while Elias Zerhouni， President Global R&D for Sanofi， said it will “create a field of opportunities for our employees， while contributing to the vitality of the local ecosystem”.1 V6 Y, |9 S$ Y

+ `% e3 r4 @, I